4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,750 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the completion of the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total value of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total value of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total value of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.67, for a total value of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.50, for a total value of $171,710.00.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $24.78 on Friday. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The business has a fifty day simple moving average of $28.97 and a 200-day simple moving average of $20.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). The firm had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. On average, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. BMO Capital Markets decreased their price objective on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, April 1st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $81.00 price target on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Barclays assumed coverage on 4D Molecular Therapeutics in a report on Monday. They set an “overweight” rating for the company. Jefferies Financial Group increased their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, Royal Bank of Canada increased their price target on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $44.22.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. Swiss National Bank increased its position in 4D Molecular Therapeutics by 6.9% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the company’s stock worth $862,000 after purchasing an additional 3,700 shares in the last quarter. JPMorgan Chase & Co. increased its position in 4D Molecular Therapeutics by 29.7% during the 1st quarter. JPMorgan Chase & Co. now owns 367,545 shares of the company’s stock worth $5,557,000 after purchasing an additional 84,158 shares in the last quarter. Bank of New York Mellon Corp increased its position in 4D Molecular Therapeutics by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 101,322 shares of the company’s stock worth $1,532,000 after purchasing an additional 1,136 shares in the last quarter. MetLife Investment Management LLC increased its position in 4D Molecular Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 17,379 shares of the company’s stock worth $263,000 after purchasing an additional 6,197 shares in the last quarter. Finally, Rhumbline Advisers increased its position in 4D Molecular Therapeutics by 14.3% during the 1st quarter. Rhumbline Advisers now owns 35,097 shares of the company’s stock worth $531,000 after purchasing an additional 4,382 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.